DelveInsight’s, “Plaque Psoriasis Pipeline Insight” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Plaque Psoriasis pipeline landscape. It covers the Plaque Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Plaque Psoriasis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Plaque Psoriasis Treatment Landscape. Click here to read more @ Plaque Psoriasis Pipeline Outlook
Key Takeaways from the Plaque Psoriasis Pipeline Report
- In January 2025:- Takeda:- The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.
- In January 2025:- Amgen:- A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis. The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
- In January 2025:- DICE Therapeutics Inc.:– A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants With Moderate-to Severe Plaque Psoriasis. The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
- In January 2025:- Janssen Pharmaceuticals:- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
- DelveInsight’s Plaque Psoriasis pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Plaque Psoriasis treatment.
- The leading Plaque Psoriasis Companies such as Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.
- Promising Plaque Psoriasis Therapies such as EDP1815, AX-158, RWJ-445380, Tapinarof cream, 1%, Bimekizumab, TAK-279 and others.
Discover groundbreaking developments in Plaque Psoriasis therapies! Gain in-depth knowledge of key Plaque Psoriasis clinical trials, emerging drugs, and market opportunities @ Plaque Psoriasis Clinical Trials Assessment
Plaque Psoriasis Emerging Drugs Profile
- ARQ-151: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase-4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases the production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the systemic treatment of plaque psoriasis and the topical treatment of atopic dermatitis. Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis.
- ABY-035: Affibody
ABY-035 is a novel bispecific agent, potently targeting both subunits of IL-17A as well as albumin. ABY-035 has been specifically designed to utilize the strengths of Affibody’s technology platform to create a very small protein drug (18 kDa, an eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin.
- AK101: Akeso Biopharma
AK101 injection is a novel antibody drug developed independently by the Company under the National Major Innovative Drug Projects. It is intended to be used for the treatment of autoimmune diseases such as psoriasis, Crohn’s disease, ulcerative colitis and lupus. AK101 clinically treats autoimmune diseases by blocking the biological activities of cytokines IL-12 and IL-23. Johnson & Johnson’s Ustekinumab (trade name: Stelara) which has the same drug targets has been approved by the FDA for the treatment of psoriasis, Crohn’s disease, and ulcerative colitis, and yielded US$6.4 billion in sales in 2019. Currently, it is in Phase III stage of clinical trial evaluation to treat Plaque Psoriasis
Stay informed about the Plaque Psoriasis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Plaque Psoriasis Unmet Needs
Plaque Psoriasis Companies
Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.
Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Plaque Psoriasis Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Transform your understanding of the Plaque Psoriasis Pipeline! See the latest progress in drug development and clinical research @ Plaque Psoriasis Market Drivers and Barriers, and Future Perspectives
Scope of the Plaque Psoriasis Pipeline Report
- Coverage- Global
- Plaque Psoriasis Companies:- Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Biocon, Pfizer, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics and others.
- Plaque Psoriasis Therapies- EDP1815, AX-158, RWJ-445380, Tapinarof cream, 1%, Bimekizumab, TAK-279 and others.
- Plaque Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Plaque Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Immunological and Autoimmune Disorders Research–Access the Full Plaque Psoriasis Pipeline Analysis Today! @ Plaque Psoriasis Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Plaque Psoriasis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Plaque Psoriasis – DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- ARQ-151: Arcutis Biotherapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- ABY-035: Affibody
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- CT303: GC Cell
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Plaque Psoriasis Key Companies
- Plaque Psoriasis Key Products
- Plaque Psoriasis- Unmet Needs
- Plaque Psoriasis- Market Drivers and Barriers
- Plaque Psoriasis- Future Perspectives and Conclusion
- Plaque Psoriasis Analyst Views
- Plaque Psoriasis Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market